Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer.
Eisai Co Ltd is developing eribulin, a simplified synthetic macrocyclic ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Phase III trials are underway in the US and Europe for patients with breast cancer. Eribulin is currently in phase II trials for NSCLC and soft tissue sarcoma, and pancreatic, prostate, ovarian, fallopian tube, peritoneal and head and neck cancer, and phase I/II trials for urothelial cancers.
Endocrinology and Metabolic Medicine, and Sterix Ltd, Faculty of Medicine, Imperial College London, St Mary's Hospital, Norfolk Place, London W2 1NY, UK. simon.newman@imperial.ac.uk
Simon
S
Newman
D000505:Alopecia / Q000139:chemically induced; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000627:therapeutic use; D017209:Apoptosis / Q000187:drug effects; D002460:Cell Line; D045744:Cell Line, Tumor; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004353:Drug Evaluation, Preclinical; D004988:Ethers, Cyclic / Q000037:antagonists & inhibitors*; D005221:Fatigue / Q000139:chemically induced; D005663:Furans / Q000737:chemistry / Q000627:therapeutic use*; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D017674:Hypophosphatemia / Q000139:chemically induced; D020128:Inhibitory Concentration 50; D007659:Ketones / Q000737:chemistry* / Q000627:therapeutic use; D018942:Macrolides; D015394:Molecular Structure; D015337:Multicenter Studies as Topic; D009325:Nausea / Q000139:chemically induced; D009369:Neoplasms / Q000145:classification / Q000188:drug therapy*; D009503:Neutropenia / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D050257:Tubulin Modulators / Q000009:adverse effects / Q000037:antagonists & inhibitors* / Q000138:chemical synthesis / Q000737:chemistry / Q000378:metabolism / Q000493:pharmacokinetics; D023041:Xenograft Model Antitumor Assays; D000095662:Polyether Polyketides
D000970:Antineoplastic Agents; D004988:Ethers, Cyclic; D005663:Furans; D007659:Ketones; D018942:Macrolides; D050257:Tubulin Modulators; C070519:halichondrin B; D000095662:Polyether Polyketides; C490954:eribulin